Dennis Ding
Stock Analyst at Jefferies
(4.10)
# 1,599
Out of 4,463 analysts
95
Total ratings
57.5%
Success rate
12.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintained: Buy | $15 | $5.16 | +190.70% | 7 | Jun 26, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintained: Buy | $40 | $33.44 | +19.62% | 4 | Jun 18, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $125 | $110.41 | +13.21% | 10 | Jun 15, 2026 | |
| SGP SpyGlass Pharma | Maintained: Buy | $62 | $19.56 | +217.05% | 4 | May 19, 2026 | |
| ESPR Esperion Therapeutics | Downgraded: Hold | $5 → $3.28 | $3.16 | +3.80% | 6 | May 4, 2026 | |
| AMPH Amphastar Pharmaceuticals | Downgraded: Hold | $22 | $20.12 | +9.34% | 1 | Apr 21, 2026 | |
| OLMA Olema Pharmaceuticals | Initiated Coverage: Buy | $40 | $12.08 | +231.13% | 1 | Mar 19, 2026 | |
| ROIV Roivant Sciences | Maintained: Buy | $18 → $30 | $35.03 | -14.36% | 16 | Feb 9, 2026 | |
| ABUS Arbutus Biopharma | Maintained: Buy | $7 | $4.73 | +47.99% | 4 | Dec 11, 2025 | |
| MLYS Mineralys Therapeutics | Maintained: Hold | $15 → $26 | $26.89 | -3.31% | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $40.25 | -50.31% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $35.17 | n/a | 14 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 → $18 | $38.14 | n/a | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $55 | $38.68 | n/a | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $1.94 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $35 | $26.72 | n/a | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 → $6 | $3.67 | n/a | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 | $3.16 | n/a | 2 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2,275 → $70 | $21.81 | n/a | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $1.95 | n/a | 3 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $35 → $22 | $88.48 | n/a | 4 | Feb 14, 2023 |
Ardelyx
Jun 26, 2026
Maintained: Buy
Price Target: $15
Current: $5.16
Upside: +190.70%
Teva Pharmaceutical Industries
Jun 18, 2026
Maintained: Buy
Price Target: $40
Current: $33.44
Upside: +19.62%
Rhythm Pharmaceuticals
Jun 15, 2026
Maintained: Buy
Price Target: $125
Current: $110.41
Upside: +13.21%
SpyGlass Pharma
May 19, 2026
Maintained: Buy
Price Target: $62
Current: $19.56
Upside: +217.05%
Esperion Therapeutics
May 4, 2026
Downgraded: Hold
Price Target: $5 → $3.28
Current: $3.16
Upside: +3.80%
Amphastar Pharmaceuticals
Apr 21, 2026
Downgraded: Hold
Price Target: $22
Current: $20.12
Upside: +9.34%
Olema Pharmaceuticals
Mar 19, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $12.08
Upside: +231.13%
Roivant Sciences
Feb 9, 2026
Maintained: Buy
Price Target: $18 → $30
Current: $35.03
Upside: -14.36%
Arbutus Biopharma
Dec 11, 2025
Maintained: Buy
Price Target: $7
Current: $4.73
Upside: +47.99%
Mineralys Therapeutics
Sep 3, 2025
Maintained: Hold
Price Target: $15 → $26
Current: $26.89
Upside: -3.31%
Jul 21, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $40.25
Upside: -50.31%
Jun 11, 2025
Maintained: Buy
Price Target: $45
Current: $35.17
Upside: n/a
May 29, 2025
Maintained: Hold
Price Target: $20 → $18
Current: $38.14
Upside: n/a
Jan 21, 2025
Upgraded: Buy
Price Target: $55
Current: $38.68
Upside: n/a
Nov 7, 2024
Initiated Coverage: Buy
Price Target: $8
Current: $1.94
Upside: n/a
Sep 19, 2024
Upgraded: Buy
Price Target: $35
Current: $26.72
Upside: n/a
Sep 3, 2024
Maintained: Hold
Price Target: $8 → $6
Current: $3.67
Upside: n/a
Jul 17, 2024
Maintained: Hold
Price Target: $1
Current: $3.16
Upside: n/a
Jun 17, 2024
Downgraded: Hold
Price Target: $2,275 → $70
Current: $21.81
Upside: n/a
Jul 13, 2023
Maintained: Buy
Price Target: $18
Current: $1.95
Upside: n/a
Feb 14, 2023
Rated: Hold
Price Target: $35 → $22
Current: $88.48
Upside: n/a